Obesity is a growing health concern worldwide. According to research, it is associated with an increased risk for cancer of at least 13 anatomic sites, including endometrial, esophageal, renal and pancreatic adenocarcinomas; hepatocellular carcinoma; gastric cardia cancer; meningioma; multiple myeloma; colorectal, postmenopausal breast, ovarian, gallbladder and thyroid cancers. Although the mechanism of this relationship is unclear, the existence of diet-based therapies (ketotherapy) as a form of cancer treatment suggests that diet somehow affects the activities of cancer cells or its environment. Preclinical studies are underway to gain a better understanding of how excess body weight affects the tumor microenvironment (TME) or how it impacts antitumor immunity.
Diet-Induced Obesity Tumor Models for Cancer Studies
June 14, 2023
- Large Panel Design to Identify Human and Mouse Lymphocyte Subsets Using Cytek® Aurora Flow Cytometers
- Featured Guest Blog: Cardiac Stem Cells by Darcey L. Clark
- The Technology Behind Spectral Flow Cytometry
- Outrunning Resistance: Why Preclinical Insight Is the Key to Durable Oncology Therapies
- New Cytometric Horizons using Spectral Flow Cytometry
Large Panel Design to Identify Human and Mouse Lymphocyte Subsets Using Cytek® Aurora Flow Cytometers
By Duangchan Suwannasaen PhD, Scientist
The Technology Behind Spectral Flow Cytometry
By Jayne Schaubhut, Lab Supervisor
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.